BioTuesdays

Tag - BTIG

Progenity-Logo

BTIG starts Progenity at buy; PT $12

BTIG initiated coverage of Progenity (NASDAQ:PROG) with a “buy” rating and price target of $12. The stock closed at $7.80 on Oct. 22. Progenity is one of the top providers of non-invasive prenatal testing (NIPT) and...

Zosano Logo

BTIG cuts Zosano Pharma PT to $2 from $7

BTIG slashed the price target for Zosano Pharma (NASDAQ:ZSAN) to $2 from $7, citing a complete response letter about the NDA for Qtrypta, a transdermal microneedle system form of zolmitriptan in development for acute...

Vericel Logo

BTIG ups Vericel PT to $30 from $23

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $30 from $23 after an analyst and investor event focused primarily on NexoBrid, a recently licensed burn enzymatic debridement product from MediWound. ...

BTIG starts Aldeyra Therapeutics at buy; PT $29

BTIG initiated coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with a “buy” rating and $29 price target. The stock closed at $6.86 on Oct. 15. Aldeyra is targeting reactive aldehyde species (RASP) for a range of...

89bio

BTIG starts 89bio at buy; PT $51

BTIG launched coverage of 89bio (NASDAQ:ETNB) with a “buy” rating and $51 price target. The stock closed at $33.14 on July 22. 89bio is developing BIO89-100, a stabilized fibroblast growth factor 21 (FGF21) analog, for...

Endologix Logo

BTIG cuts Endologix to neutral; removes price target

BTIG downgraded Endologix (NASDAQ:ELGX) to “neutral” without a price target, citing “greater uncertainty” that the potential COVID-19 impact on revenue could put the company’s financial covenants in peril. The stock...

Axcella Logo

BTIG starts Axcella Health at buy; PT $10

BTIG launched coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $10 price target. The stock closed at $4.66 on April 30. “We view Axcella’s calculated approach to correcting metabolic diseases with...

Mersana Therapeutics Logo

BTIG starts Mersana Therapeutics at buy; PT $14

BTIG launched coverage of Mersana Therapeutics (NASDAQ:MRSN) with a “buy” rating and $14 price target. The stock closed at $9.36 on April 28. Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer...

Centogene Logo

BTIG ups Centogene PT to $23 from $18

BTIG raised its price target for Centogene (NASDAQ:CNTG) to $23 from $18, citing a “solid execution” in its pharma and diagnostics segments in 2019. The stock closed at $18.69 on April 23. Analyst Sung Ji Nam writes...

Arcus Biosciences

BTIG ups Arcus Biosciences PT to $34 from $20

BTIG raised its price target for Arcus Biosciences (NYSE:RCUS) to $34 from $20, citing investors meetings with Arcus management that “reinforced careful development of important assets.” The stock closed at $15.58 on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.